Valley Wealth Managers’s VanEck Biotech ETF BBH Stock Holding History

Valley Wealth Managers’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-19,308	Closed	-$3.21M	–	388
2024 Q1	$3.21M	Buy	19,308 +2,146	+13%	+$355K	0.24%	101
2023 Q4	$2.84M	Sell	17,162 -1,821	-10%	-$280K	0.22%	102
2023 Q3	$2.96M	Buy	+18,983	New	+$3.03M	0.25%	104

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Valley Wealth Managers's BBH Position: Q2 2024 in Review

Valley Wealth Managers sold out of VanEck Biotech ETF (BBH) in Q2 2024, closing a stake of 19,308 shares — an estimated $3.21M sold.

Valley Wealth Managers first reported a position in BBH in Q3 2023 and held it in 3 quarters. The position peaked at $3.21M in Q1 2024. 116 funds tracked by Wall St. Rank hold BBH as of Q2 2024.

Valley Wealth Managers reported no remaining VanEck Biotech ETF position as of Q2 2024 after selling out during the quarter.
Valley Wealth Managers sold 19,308 VanEck Biotech ETF shares in Q2 2024, an estimated $3.21M.
Valley Wealth Managers first reported a position in VanEck Biotech ETF in Q3 2023 and held it in 3 quarters.
Valley Wealth Managers's VanEck Biotech ETF position peaked at $3.21M in Q1 2024.
116 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2024.

Based on Valley Wealth Managers's 13F filing for Q2 2024, filed 8 Aug 2024.